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Introduction: Primary malignant melanoma of the vagina is an extremely rare disease affecting 3% of patients with
malignant vaginal tumors. It is rare compared to primary malignant melanoma of the skin and its prognosis is
unfavorable even in patients with Stage I disease. Here, we report a case of primary malignant melanoma of the
vagina and discuss our experience with regard to previously published literature.
Case description: The patient was a 59-year-old female with 2 prior pregnancies and child births. She was examined by a
local doctor for swelling of the genitalia, and a 1.8 × 1.0 cm large tumor was detected on the left side of the vaginal wall. A
biopsy indicated leiomyosarcoma, and she was referred to our hospital. The tumor was resected, and histopathology of the
resected sample confirmed the diagnosis of malignant melanoma based on a positive surgical margin. Additional courses
of treatment included left inguinal sentinel lymph node biopsy using an isotope and extended vaginectomy. Although the
sentinel node was negative, we performed a modified radical hysterectomy and left vaginectomy during the third
operation because the surgical margin was positive. We could not confirm whether the lesion in the extracted sample
was malignant, and the final diagnosis was primary malignant melanoma of the vagina T4bN0M0 Stage IIc (UICC 2009).
Postoperative adjuvant therapy consisted of 6 cycles of DAV-Feron therapy (dacarbazine, ACNU, vincristine, IFN- β). After
5 months of postoperative adjuvant therapy, a 2 cm single lung metastasis was detected in the lower left lung. We
performed a laparoscopic lower left lobectomy and are planning additional chemotherapy.
Discussion and evaluation: Currently, surgical resection has the highest probability of improving the prognosis
of patients when used as initial treatment for Stage I disease. By combining treatment with sentinel lymph node
biopsy, we were able to accurately determine the stage of disease and thus avoid systematic lymph node
dissection and further surgical treatments.
Conclusion: Malignant melanoma of the vagina is very rare tumor so it is necessary to requires the integration of
further cases.
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Primary malignant melanoma of the vagina is an ex-
tremely rare condition that affects 1% of women with
malignant melanoma and less than 3% of women with
malignant tumors of the vagina (Piura et al. 2002;
Gokaslan et al. 2005; Nakagawa et al. 2002).
Compared to normal malignant tumors of the skin,
hematogenous and lymphogenous metastasis occurs
more frequently in malignant melanoma of the vagina.
and unfavorable prognosis even in early stage disease
(Frumovitz et al. 2010). We report our experience with a
patient who presented with primary malignant melanoma
and discuss our findings with regard to previously pub-
lished literature.Figure 1 We confirmed a white, vaginal wall tumor 1.8 × 1.0 cm in siz
by speculum examination.Case description
The patient was a 59-year-old female with 2 prior preg-
nancies and child births and no particular prior medical
or family history. In January 2012, she noticed swelling
in the genitals and sought the advice of a local obstetri-
cian/gynecologist. A tumor measuring 2 cm was de-
tected on the left side 1 cm from the vaginal opening.
She was diagnosed with a tumor of the vaginal wall (spindle
cell tumor) based on the results of biopsy and histopath-
ology, and she was referred to our clinic. We confirmed the
presence of a white, vaginal wall tumor 1.8 × 1.0 cm in size
(Figure 1) located on the left side, 1 cm from the vaginal
opening by speculum examination. No abnormalities in the
initial blood biochemistry or tumor marker values weree on the left side of the vagina, 1 cm from the vaginal opening,
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RBC, 437/μl; Hb, 13.6 g/dl; Plt, 20.4 × 104/μl; LDH, 195 μl;
CRP, 0.0 mg/dl; CEA, 3.2 ng/ml; CA125, 14 U/ml; CA19-9,
21 U/ml; and SCC, 0.7 ng/ml.
Histological diagnosis: spindle cell tumor with suspi-
cion of leiomyosarcoma (Figure 2a).Figure 2 Vaginal wall tumor resection. (a) Diagnosis of spindle cell tum
mm and brown pigmentation in the cytoplasm (H&E 1×,40×) (c) immunos
HMB45, and Melan-A (40×).No clear evidence of distant metastasis or vaginal wall
tumors was obtained by CT examination or pelvic MRI.
Histopathological diagnosis performed using specimens
from the previous doctor indicated spindle cell tumor sus-
picious of leiomyosarcoma, and a vaginal wall tumor re-
section was qa 1 cm surrounding margin. Histopathologyor suspicious of leiomyosarcoma. (H&E100×) (b) tumor thickness of 8.5
taining revealed that the tumor cells were Positive for S-100 protein,
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positive surgical margin (Figure 2b, 2c).
An FDG-PET-CT scan was performed after the first op-
eration to rule out the presence of remaining lesions or
distant metastasis. The results showed an area of high
FDG accumulation on the left side of the vagina; however,
tracer accumulation in the lymph nodes or evidence of
distant metastasis was not found (Figure 3a).
In preparation for additional surgery including sentinel
lymph node biopsy, we injected m99Tc into the region
of the vaginal wall tumor 1 day before surgery, and con-
firmed the accumulation of m99Tc 2 hours later in the
left inguinal to retroperitoneal lymph node (Figure 3b).
A second surgery was performed 35 days after the first
operation. We found surgical scars from the previous
operation 1 cm from the vaginal opening on the left side.
Therefore, the tumor was resected with a 2 cm margin and
resection of the vaginal wall was performed. A sentinel
lymph node (left superficial inguinal lymph node) biopsy
was performed using an isotope, which did not detect
lymph node metastasis (0/3) in a rapid histopathological
examination. Therefore, pelvic and inguinal lymph node
metastasis was not performed.Figure 3 PET examination and nuclear medicine scan (a) high accumu
(arrow) (b) Accumulaion of m99Tc in the left inguinal to retroperitonHistopathological analysis of the resected samples re-
vealed malignant melanoma, and a microscopic distance
of 0.3 mm was observed between the resected margin of
the vaginal wall and the tumor. This indicated that the
resected region did not fall within the safety margin and
an additional surgery was scheduled. A third surgery was
performed 35 days after the second operation. To ensure
adequate vaginal wall resection, we performed an ab-
dominal modified radical hysterectomy followed by a
left-side vaginectomy.
Surgical findings: We performed an abdominal modi-
fied radical hysterectomy. After processing the anterior
layer of the vesico-uterine ligament bilaterally, we sepa-
rated the bladder from the vaginal wall from the outside
of the left abdominal cavity. We then processed the
paravaginal tissue on the left side by accessing it from
the abdominal side; vaginal wall resection was performed
by approaching it from the external genitalia. Finally, we
penetrated the abdominal cavity and the left side of the
vagina, and removed the left side of the vagina and the
uterus together.
A modified radical hysterectomy was selected instead of
a simple total hysterectomy to ensure adequate excision oflation of FDG was confirmed in the left side of the vagina
eal lymph nodes (arrow).
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we excised the vesical branches of the pelvic splanchnic
nerve on the left side to ensure adequate separation of the
bladder from the vaginal wall on the left side. We did not
opt for total resection of the vaginal wall, as a similar ap-
proach from the right would have ensured post-operative
dysuria. Instead, we limited the operation to the left side.
The total time required for the procedure was 8 hours
30 minutes with a blood loss of 1440 ml. As shown in the
analysis of the extracted sample (Figure 4), we found no
evidence of remaining malignant tissue.
The final diagnosis was primary malignant melanoma
of the vagina T4bN0M0 Stage IIc (UICC 2009), based on
the tumor size of 2 cm, over 4 mm of interstitial inva-
sion, the lack of evidence of metastasis to the inguinal
lymph nodes extracted as sentinel lymph nodes, and the
lack of evidence of distant metastasis.
A 6-course postoperative adjuvant therapy with DAV-
Feron was planned (Table 1). Four courses of DAV-Feron
treatment were administered between June and November
2012. Although a fifth course of therapy was planned, the
patient developed grade 4 thrombocytopenia and the
treatment was changed to 2 courses of locally injected
Feron-only therapy. At 5 months after terminating the
adjuvant therapy (18 months after the initial treatment),
a 2 cm single lung metastasis was detected in the lower-Figure 4 Uterine-bladder sample from the third surgery (macro). The
eye (arrow).left lung field. It was diagnosed as recurrence of the malig-
nant melanoma of the vaginal wall metastasized to the
lungs, and we performed a laparoscopic lower left lobec-
tomy. Analysis of the resected sample revealed relapsed
malignant melanoma with a negative surgical margin. Add-
itional chemotherapy is currently being planned.
Discussion
Primary malignant melanoma of the vagina is an ex-
tremely rare condition that affects 1% of women with
malignant melanoma and less than 3% of women diag-
nosed with malignant tumors of the vagina. Approxi-
mately 250 cases have been reported in the literature
and 0.026 in 100,000 people are expected to present with
this condition each year (Piura et al. 2002; Gokaslan
et al. 2005; Nakagawa et al. 2002). Approximately 3% of
females have melanocytes (melanin-producing pigment
cells) in the basement membrane of the epithelium of
the vaginal mucous membrane, which can be the site of
onset of primary malignant melanoma of the vagina
(Gokaslan et al. 2005). Approximately 80% of cases
occur post-menopause with an average age of onset of
60 years, and the primary symptom is vaginal bleeding
(Frumovitz et al. 2010). A study showed that 84% of pa-
tients are Caucasian (Frumovitz et al. 2010). Most cases
occur in the lower third of the vagina on the anteriorscar from the previous surgery could be confirmed with the naked
Table 1 DAV-Feron chemotherapy
day1 day2 day3 day4 day 5
DTIC: 120 mg/m2/day, iv. ↓ ↓ ↓ ↓ ↓
ACNU: 60 mg/m2/day, iv. ↓
VCR: 0.6 mg/m2/day, iv ↓
Feron: 3,000,000 E/body/day,
local injection
↓ ↓ ↓ ↓ ↓
Every 4-6 weeks, total 5-6 courses.
DTIC: Dacarvazine, ACNU : Nimustine hydrochloride, VCR : Vincristine, Feron : INF-β.
↓: Chemotherapy is performed.
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melanoma often presents with pigmentation, our patient
was amelanotic. Reports suggest that amelanotic cases
account for less than 10% of all cases (Nakagawa et al.
2002).
In the determination of the clinical stage of primary
malignant melanoma of the vagina, the staging classifica-
tion of the International Federation of Gynecology and
Obstetrics (FIGO), which is used in vaginal cancers,
does not combine tumor size and lymph node metasta-
sis. Instead, staging of primary malignant melanoma of
the vagina is based on the classification of the Union for
International Cancer Control 2009 (UICC), which is
used for the staging of malignant melanoma.
Several advanced cases of primary malignant melan-
oma of the vagina have been reported, and the prognosis
is extremely poor even in early stage disease. Frumovitz
et al. reported that the 5-year survival rate for Stage I
primary malignant melanoma of the skin is 81% com-
pared to 18% for melanoma originating in the vagina.
The authors analyzed 37 patients with Stage I primary
malignant melanoma of the vagina and reported a 5-year
progression-free survival rate of 9.5% and a 5-year over-
all survival rate of 20.0% (Frumovitz et al. 2010).
Frumovitz et al. reported on the effectiveness of surgical
therapies for primary malignant melanoma of the vagina.
These authors found that patients treated with only ra-
diation or chemotherapy as initial treatment for Stage I
primary malignant melanoma of the skin had an average
survival of 8.7 months, compared to 24–32 months for
those that also received prior surgical therapies, which
was a significant increase (P = 0.01) in survival (Frumovitz
et al. 2010).
However, with respect to the surgical methods, they
reported no significant differences between patients who
underwent lesion excision, radical surgery, or pelvic ex-
enteration (Frumovitz et al. 2010). Pelvic exenteration
often presents with surgery-related complications, which
prevents it from becoming a standard therapy, especially
if adjuvant therapies are considered. The definitiveness
of local excision of lesions can be a problem in addition
to the possibility of local recurrence associated with this
surgical method.Therapeutic considerations such as the systematic re-
moval of inguinal and pelvic lymph nodes in primary
malignant melanoma of the vagina are uncommon; how-
ever, lymph node metastasis is a prognostic factor.
Therefore, the detection of lymph node metastasis is ne-
cessary. However, considering the invasiveness of surgical
intervention, operations should be limited as much as pos-
sible. In general, sentinel lymph node biopsies are indi-
cated in patients with malignant melanoma and are used
frequently in other primary sites (Lens et al. 2002). The
MSLT-1 study investigated the effectiveness of sentinel
lymph node biopsies, and we performed sentinel lymph
node biopsies based on this theoretical background.
To determine whether sentinel lymph node biopsies
improved survival rates in all cases of malignant melan-
oma, a randomized, comparative trial was conducted in
collaboration with 17 institutions (MSLT-1). In this trial,
1269 patients with primary tumor thicknesses between
1.2 mm and 3.5 mm were divided into 2 groups consisting
of 769 patients receiving sentinel lymph node biopsies and
500 patients receiving primary lesion resection only
(dissection was performed after discovery of lymph node
metastasis during post-operative periodic observations).
The results showed that the 5-year progression free
survival rate in patients with biopsies was 78.3 ± 1.3%
compared to 73.1 ± 2.1% for those without, which was a
significant increase in the former group (P = 0.009,
death HR: 0.74) (Morton et al. 2006).
Our study also demonstrated that lymph node dissec-
tion should be performed early if sentinel lymph node bi-
opsies reveal metastasis by microscopy, instead of waiting
until metastasis is observed during periodic observation
after primary tumor resection. However, whether lymph
node dissection itself can affect prognosis remains to be
elucidated (Morton et al. 2006).
In the present study, we performed sentinel lymph node
biopsy of the left superficial inguinal lymph nodes using
an isotope. We were able to omit systematic lymph node
dissection by confirming the absence of inguinal lymph
node metastasis (-) through rapid pathological diagnosis.
Postoperative adjuvant therapy is the treatment of
choice in patients with regional lymph node metastasis
and primary malignant tumors of the skin larger than
4 mm. Currently, DAV-Feron therapy (DTIC/ACNU/
VCR combination therapy with interferon β injection at
the site of the operative wound) is the standard therapy
for melanoma internationally. A multi-center trial inves-
tigated the effectiveness of adjuvant therapy after radical
operations for previous-UICC stage II and III patients
(thickness >4 mm or positive regional lymph nodes) in
Japan. The results showed that compared with historical
controls treated with DAV only, the combined therapy
significantly improved the 5-year survival rate (65.1% vs.
46.2%; P < 0.05) (Yamamoto & Ishikawa 1996).
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present patient; however, we selected DAV-Feron ther-
apy because the tumor was larger than 4 mm.
Other therapies for melanomas with distal metastasis
currently include high-dose IL-2 therapy and molecular
targeted drugs.
High-dose IL-2 therapy has a response rate of approxi-
mately 15% and a complete response rate of 6%; however,
it is associated with severe adverse reactions and is there-
fore not considered beneficial. Nevertheless, long-term,
relapse-free survival was reported in a low percentage of
patients (approximately 5%) (Atkins et al. 1998).
The molecular targeted drug BAY 43-9006 (sorafenib),
a Raf-1 inhibitor, is noteworthy. In addition to inhibiting
the MAPK signaling pathway, this drug also inhibits tyro-
sine kinase receptors associated with angiogenesis such
as VEGFR-2, VEGFR-3, PDGFR- β, Flt-3, and c-KIT. In a
phase I/II clinical trial, sorafenib combined with carbo-
platin/paclitaxel achieved impressive results with a par-
tial response rate of 40% and a stable disease (SD) rate
of 43%. A phase III clinical trial is currently underway
(Strumberg 2005).
Conclusions
The prognosis of mucous membrane-derived malignant
melanomas, including those in the vaginal wall, is poor
compared to those derived from the skin. Currently, sur-
gical resection has the highest probability of improving
the prognosis of patients when used as initial treatment
for Stage I disease. By combining treatment with sentinel
lymph node biopsy, we were able to accurately deter-
mine the stage of disease and thus avoid systematic
lymph node dissection and further surgical treatments.
We anticipate that post-operative adjuvant DAV-Feron
therapy could be combined with molecular targeted
drugs such as sorafenib in the future.
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